differences across the specialties. A total of 43% (157 of 368) of total cases involved death of the patient. Among the four specialties, there was a significant (P ¼ .0004) difference in the primary allegation (informed consent, preprocedure negligence, intraprocedural complications, or postprocedural complications) underlying the litigation (Fig). For CTS and VS, there was a predominance of informed consent and preprocedure negligence allegations (70% [7 of 10] and 52% [28 of 54] respectively). Intraprocedural negligence was the most common allegation for IR (59% [23 of 39]), while allegations were more evenly distributed among IC.
differences across the specialties. A total of 43% (157 of 368) of total cases involved death of the patient. Among the four specialties, there was a significant (P ¼ .0004) difference in the primary allegation (informed consent, preprocedure negligence, intraprocedural complications, or postprocedural complications) underlying the litigation (Fig) . For CTS and VS, there was a predominance of informed consent and preprocedure negligence allegations (70% [7 of 10] and 52% [28 of 54] respectively). Intraprocedural negligence was the most common allegation for IR (59% [23 of 39]), while allegations were more evenly distributed among IC.
Conclusions: Key issues were identified regarding malpractice litigation involving the specialties that commonly perform endovascular procedures. Despite the increasing number of ICs doing peripheral interventions, a large majority of IC cases were related to coronary treatments. A surprisingly large percentage of VS cases were related to seemingly minor cases. There were significant interspecialty differences in the primary underlying allegations. As the scope of endovascular procedures broadens and deepens, it is important for clinicians to be aware of the legal considerations relevant to their practice.
Author Disclosures: S. Muluk: Nothing to disclose; K. Oh: Nothing to disclose; G. E. Savulionyte: Nothing to disclose. Objectives: Endovascular repair (EVAR) has become the preferred approach to abdominal aortic aneurysm (AAA) due to decreased early morbidity and mortality compared with open repair. However, the ability of EVAR to prevent long-term aneurysm-related mortality (ARM) has been questioned in light of recent trial data. We report our updated long-term EVAR experience in a large multicenter registry to further examine this issue.
VESS05.

Long-Term
Methods: Between 2000 and 2010, 1736 patients with AAA underwent EVAR in a large integrated regional health care system. We extended follow-up in this previously reported cohort through 2015 and identified predictors associated with ARM and need for major reintervention. Primary outcomes were all-cause mortality and ARM. Secondary outcomes were delayed aneurysm rupture, major adverse event (open conversion, major embolic event, graft infection requiring explantation, graft occlusion requiring treatment, aneurysm rupture, graft migration requiring treatment, other), major reintervention (open or endovascular revision), sac growth >5 mm, and type I or III endoleak.
Results: Overall follow-up rate was 97.9%, and median follow-up was 5.5 years (interquartile range, 2.8-7.7). During the study period 958 patients died, of whom 63 experienced ARM (6.6%). Overall freedom from ARM was 96.4%. Life-table analysis at 5 and 10 years showed cumulative survival of 64.4% and 34.6% and freedom from ARM of 96.9% and 94.8%, respectively. Delayed aneurysm rupture was seen in 1.3% (n ¼ 23), with median time to event of 4.1 years (interquartile range, 1.7-7.2). Major adverse event was seen in 12.4%, and major reintervention was performed in 10.3% of patients. Overall freedom from a major adverse event or major reintervention was seen in 84.0%. Sac growth was present in 35.2%. Rates of type I and III endoleak were 7.1% and 2.5%, respectively. Significant predictors of ARM included female sex, age 80-89 years, preoperative AAA size $5.5 cm, urgent EVAR, and any major reintervention. Significant predictors of need for major reintervention included preoperative AAA size $5.5 cm, urgent EVAR, and peripheral vascular disease.
Conclusions: Our results demonstrate favorable long-term freedom from major adverse event or major reintervention after EVAR and extremely low rates of ARM and delayed rupture. This suggests that the higher rates of delayed rupture and ARM seen in other long-term cohorts may not be generalizable to patients who have undergone EVAR with more contemporary devices. Our findings support EVAR as a safe longterm solution for managing patients with AAA and may provide insight into clinical parameters that can be used to stratify patients' post-EVAR surveillance and need for reintervention.
Author Disclosures: R. W. Chang: Nothing to disclose; P. Goodney: Nothing to disclose; B. Hill: Nothing to disclose; H. Hua: Nothing to disclose; S. P. Okuhn: Nothing to disclose; N. C. Rich: Nothing to disclose; L. Tucker: Nothing to disclose. Objectives: The ideal treatment for submassive pulmonary embolism (PE) remains undefined. The objective of this study was to evaluate the efficacy of ultrasound-accelerated catheter-directed thrombolytic therapy in patients with submassive PE.
VESS06.
Methods: Clinical records of 46 patients (25 males and 21 females; mean age, 56.8 years; age range, 32-74 years) with submassive PE who underwent ultrasound-accelerated catheter-directed pulmonary thrombolysis using tissue plasminogen activator (tPA) from 2009 to 2017 were analyzed. All patients experienced clinical symptoms with computed tomography (CT) evidence of pulmonary thrombus burden. Right ventricular dysfunction (RVD) was present in all patients by the echocardiographic finding of a RV-to-left ventricle (RV:LV) ratio >0.9. Treatment outcome, procedural complications, RV pressures, and thrombus clearance were evaluated. Follow-up evaluation include echocardiographic assessment of RV:LV ratio at 1 month, 6 months, and 1 year. Treatment success was defined by the following conditions: restoration of hemodynamic status, improvement of pulmonary hypertension, improvement of RVD, and survival to hospital discharge. Primary safety outcomes were major procedure-related complications and hemorrhagic episodes.
Results: Technical success was achieved in all patients (n ¼ 46 [100%]). Our patients received an average of 27.5 6 2.5 mg of tPA using an ultrasound-accelerated thrombolytic infusion catheter with an average treatment time of 18.6 6 4.6 hours. Clinical success was achieved in 45 patients (98%; 95% confidence interval, 92.4%-99.5%). Significant reduction of mean pulmonary artery pressure occurred after the treatment, which decreased from 53.6 6 16.4 to 32.6 6 18.3 mm Hg (P # .0001). There were two bleeding complications with groin hematoma and flank ecchymosis (n ¼ 2 [4%]), which were treated conservatively. All-cause mortality at 30 days was 0%. No patient developed recurrent PE during follow-up. 
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There were no readmissions for PE at 30 days after discharge. During the follow-up period, 43 patients (93%; 95% confidence interval, 79.3%-96.7%; P # .0001) showed improvement of RVD based on echocardiographic assessment. The modified Miller score was significantly improved from 32 6 5 to 14 6 6 at the time of hospital discharge in 42 patients (91%; P < .001). The RV:LV ratio decreased from 1.29 6 0.17 to 0.92 6 0.11 at the 1-month follow-up (P < .001). The RV function remained improved at 6 months and 1 year of follow-up, as RV:LV ratios were 0.95 6 0.14 (P < .001) and 0.93 6 0.15 (P < .001), respectively. Conclusions: Ultrasound-accelerated catheter-directed thrombolysis is an efficacious treatment for submassive PE with low complication rates. It reduces pulmonary hypertension and improves RV function in patients with submassive PE.
Author Disclosures: C. Bechara: Nothing to disclose; S. Duchman: Nothing to disclose; A. Echeverria: Nothing to disclose; E. Kfoury: Nothing to disclose; P. H. Lin: Nothing to disclose; J. Varon: Nothing to disclose. Objectives: This study was conducted to understand drivers of cost for carotid endarterectomy (CEA) and carotid artery stenting (CAS) and to compare variation in cost among cases performed by vascular surgery with other services.
VESS07.
Variability in Hospital Costs for Carotid Artery Revascularization
Methods: We collected internal hospital claims data for CEA and CAS between September 2013 and August 2015 and performed a financial analysis of all hospital costs using standardized categories, including room accommodations, medications, medical and surgical supplies, imaging, and laboratory analysis. Cases were stratified by presence of symptoms and procedure type, and costs of procedures performed by vascular surgeons (VS) were compared with those performed by other services (OS).
Results: The cohort comprised 144 patients (78 asymptomatic, 66 symptomatic; 44 CAS, 100 CEA). VS (24 CAS, 70 CEA) and neurosurgery/neurointerventional radiology (20 CAS, 30 CEA) performed all procedures. Age (71 6 9 vs 70 6 11 years; P ¼ .8) and length of stay (1.7 6 2.1 vs 2.2 6 2.4 days; P ¼ .73) were similar for VS and OS. Case-mix index was similar after stratifying by symptoms (asymptomatic: 1.28 6 0.35 vs 1.39 6 0.42, P ¼ .5; symptomatic: 1.67 6 0.73 vs 1.82 6 0.81; P ¼ .9). Average hospital costs were 37% lower for asymptomatic patients. Costs were 37% higher for CAS vs CEA for asymptomatic patients and 11% higher for symptomatic patients. The largest cost components were operating room (OR) utilization, beds, and supplies, together accounting for 71% of costs. For asymptomatic CAS, average hospitalization cost was 16% less for VS compared with OS due to 44% lower OR utilization costs, 40% lower medication costs, and 78% lower intensive care unit costs. VS had 25% higher supply costs and used 16% more cardiac services. For asymptomatic CEA, average index hospitalization costs were 22% lower for VS, driven by lower utilization of OR services (28%), medications (28%), imaging (62%), and neurointerventional monitoring (64%). Symptoms were present prior to revascularization for 61%, and were more commonly treated by OS (78% vs 29%; P < .001). For symptomatic CAS, costs were similar for both groups. For symptomatic CEA, total costs were 14% lower for VS compared with OS, driven by 25% lower OR, 62% lower neurointerventional monitoring, 20% lower monitored beds, and 28% lower supply costs (and counter-balanced by 116% higher intensive care unit costs).
Conclusions: VS average hospital costs were lower for asymptomatic CAS and all CEA compared with other services. Drivers of higher cost appear to be attributed to variation in physician practice as well as patient complexity, affording an opportunity to reduce cost.
Author Disclosures: R. Dalman: Nothing to disclose; H. Jolly: Nothing to disclose; C. Kell: Nothing to disclose; R. Lew: Nothing to disclose; M. W. Mell: Nothing to disclose; D. Patterson: Nothing to disclose; S. Sigurdsson: Nothing to disclose; N. Tang: Nothing to disclose. Results: A total of 53 patients (68% men; mean age, 50.1 years) were treated over the study period. Indications for operation were venous thoracic outlet syndrome (n¼ 19) or CCJ stenosis associated with ipsilateral dialysis access (n ¼ 34). Eight patients underwent on-table thrombolysis for acute occlusion. All patients underwent CCJ decompression, 48 via infraclavicular first rib resection and five via claviculectomy. Five patients underwent sternoclavicular rotation for further exposure. Surgical reconstruction of the vein was used in 18 patients (34%): 9 underwent interposition grafting, 1 jugular turndown, and 8 patch angioplasty. Endovascular procedures were performed in 43 patients (81.1%): 24 underwent venous angioplasty alone, and 15 underwent stenting. Median length of stay was 4 days, with mean operative time of 135 6 63.5 minutes, and estimated blood loss of 244 6 261 mL. Perioperative complications were noted in 14 patients (26.4%) including wound complications (n ¼ 6), cardiac (n ¼ 4), reocclusion (n ¼ 3), and hemothorax requiring chest tube placement (n ¼ 1). Mean follow-up was 13.4 (0.6-58.5) months. Symptom relief was experienced in 100% of patients. During follow-up 5 patients (9.4%) developed recurrent symptoms, 6 (11.3%) reoccluded their central system, and 16 (30.2%) required reintervention for restenosis. Mean time to reintervention was 134 6 285 days. Methods: A retrospective cohort study was conducted and included all patients who underwent an open infrainguinal revascularization procedure before and after 2014. Since 2014, we have implemented strategies to reduce postoperative wound complications, among which include
VESS08.
Methods and Outcomes of Surgical and Endovascular Central Venous Reconstruction Combined With Thoracic Outlet Decompression
